147 related articles for article (PubMed ID: 17656591)
41. Refractory pituitary adenoma: a novel classification for pituitary tumors.
Dai C; Feng M; Liu X; Ma S; Sun B; Bao X; Yao Y; Deng K; Wang Y; Xing B; Lian W; Zhong D; Ma W; Wang R
Oncotarget; 2016 Dec; 7(50):83657-83668. PubMed ID: 27845901
[TBL] [Abstract][Full Text] [Related]
42. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
[TBL] [Abstract][Full Text] [Related]
43. Clinicopathological study of prognostic factors in patients with pituitary adenomas and Ki-67 labeling index of more than 3%.
Ogawa Y; Ikeda H; Tominaga T
J Endocrinol Invest; 2009 Jul; 32(7):581-4. PubMed ID: 19509474
[TBL] [Abstract][Full Text] [Related]
44. NRP-1 expression is strongly associated with the progression of pituitary adenomas.
Lee SW; Lee JE; Yoo CY; Ko MS; Park CS; Yang SH
Oncol Rep; 2014 Oct; 32(4):1537-42. PubMed ID: 25109698
[TBL] [Abstract][Full Text] [Related]
45. Contribution of immunohistochemistry, electron microscopy, and cell culture to the characterization of nonfunctioning pituitary adenomas: a study of 40 cases.
Croue A; Beldent V; Rousselet MC; Guy G; Rohmer V; Bigorgne JC; Saint-Andre JP
Hum Pathol; 1992 Dec; 23(12):1332-9. PubMed ID: 1468769
[TBL] [Abstract][Full Text] [Related]
46. Endoscopic endonasal surgery for giant pituitary adenomas: advantages and limitations.
Koutourousiou M; Gardner PA; Fernandez-Miranda JC; Paluzzi A; Wang EW; Snyderman CH
J Neurosurg; 2013 Mar; 118(3):621-31. PubMed ID: 23289816
[TBL] [Abstract][Full Text] [Related]
47. Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the risk of tumor recurrence.
Losa M; Mortini P; Barzaghi R; Ribotto P; Terreni MR; Marzoli SB; Pieralli S; Giovanelli M
J Neurosurg; 2008 Mar; 108(3):525-32. PubMed ID: 18312100
[TBL] [Abstract][Full Text] [Related]
48. The human gonadotropic adenoma: pathologic diagnosis and hormonal correlations in 26 tumors.
Trouillas J; Girod C; Sassolas G; Claustrat B
Semin Diagn Pathol; 1986 Feb; 3(1):42-57. PubMed ID: 3112888
[TBL] [Abstract][Full Text] [Related]
49. Role of Ki-67 in acromegalic patients with hyperprolactinemia: retrospective analysis in 61 Chinese Patients.
Huan C; Cui G; Lu C; Qu X; Han T
Pak J Pharm Sci; 2015 Mar; 28(2 Suppl):719-23. PubMed ID: 25796164
[TBL] [Abstract][Full Text] [Related]
50. Silent corticotroph adenomas have unique recurrence characteristics compared with other nonfunctioning pituitary adenomas.
Cho HY; Cho SW; Kim SW; Shin CS; Park KS; Kim SY
Clin Endocrinol (Oxf); 2010 May; 72(5):648-53. PubMed ID: 19650787
[TBL] [Abstract][Full Text] [Related]
51. Pathobiology of pituitary adenomas and carcinomas.
Scheithauer BW; Gaffey TA; Lloyd RV; Sebo TJ; Kovacs KT; Horvath E; Yapicier O; Young WF; Meyer FB; Kuroki T; Riehle DL; Laws ER
Neurosurgery; 2006 Aug; 59(2):341-53; discussion 341-53. PubMed ID: 16883174
[TBL] [Abstract][Full Text] [Related]
52. Factors That Predict the Growth of Residual Nonfunctional Pituitary Adenomas: Correlations between Relapse and Cell Cycle Markers.
Matoušek P; Buzrla P; Reguli Š; Krajča J; Dvořáčková J; Lipina R
Biomed Res Int; 2018; 2018():1876290. PubMed ID: 30112364
[TBL] [Abstract][Full Text] [Related]
53. Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up.
Raverot G; Wierinckx A; Dantony E; Auger C; Chapas G; Villeneuve L; Brue T; Figarella-Branger D; Roy P; Jouanneau E; Jan M; Lachuer J; Trouillas J;
J Clin Endocrinol Metab; 2010 Apr; 95(4):1708-16. PubMed ID: 20164287
[TBL] [Abstract][Full Text] [Related]
54. Overexpression of EpCAM and Trop2 in pituitary adenomas.
Chen X; Pang B; Liang Y; Xu SC; Xin T; Fan HT; Yu YB; Pang Q
Int J Clin Exp Pathol; 2014; 7(11):7907-14. PubMed ID: 25550831
[TBL] [Abstract][Full Text] [Related]
55. Improved versus worsened endocrine function after transsphenoidal surgery for nonfunctional pituitary adenomas: rate, time course, and radiological analysis.
Jahangiri A; Wagner JR; Han SW; Tran MT; Miller LM; Chen R; Tom MW; Ostling LR; Kunwar S; Blevins L; Aghi MK
J Neurosurg; 2016 Mar; 124(3):589-95. PubMed ID: 26252454
[TBL] [Abstract][Full Text] [Related]
56. Endoscopic transsphenoidal treatment in recurrent and residual pituitary adenomas--first experience.
Rudnik A; Zawadzki T; Gałuszka-Ignasiak B; Bazowski P; Duda I; Wojtacha M; Rudnik AI; Krawczyk I
Minim Invasive Neurosurg; 2006 Feb; 49(1):10-4. PubMed ID: 16547875
[TBL] [Abstract][Full Text] [Related]
57. Effects of octreotide treatment on the proliferation and apoptotic index of GH-secreting pituitary adenomas.
Losa M; Ciccarelli E; Mortini P; Barzaghi R; Gaia D; Faccani G; Papotti M; Mangili F; Terreni MR; Camanni F; Giovanelli M
J Clin Endocrinol Metab; 2001 Nov; 86(11):5194-200. PubMed ID: 11701676
[TBL] [Abstract][Full Text] [Related]
58. Pituitary adenomas in childhood and adolescence.
Kane LA; Leinung MC; Scheithauer BW; Bergstralh EJ; Laws ER; Groover RV; Kovacs K; Horvath E; Zimmerman D
J Clin Endocrinol Metab; 1994 Oct; 79(4):1135-40. PubMed ID: 7525627
[TBL] [Abstract][Full Text] [Related]
59. MRI texture analysis as a predictor of tumor recurrence or progression in patients with clinically non-functioning pituitary adenomas.
Galm BP; Martinez-Salazar EL; Swearingen B; Torriani M; Klibanski A; Bredella MA; Tritos NA
Eur J Endocrinol; 2018 Sep; 179(3):191-198. PubMed ID: 29973377
[TBL] [Abstract][Full Text] [Related]
60. Clinicopathologic correlates of giant pituitary adenomas.
Chacko G; Chacko AG; Lombardero M; Mani S; Seshadri MS; Kovacs K; Scheithauer BW
J Clin Neurosci; 2009 May; 16(5):660-5. PubMed ID: 19285407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
